Consonance Capital Management LP
Legal Name: CONSONANCE CAPITAL MANAGEMENT LP
Full Contact Details
Consonance Capital Management LP
1370 AVENUE OF THE AMERICAS, FLOOR 33, NEW YORK, NY
212-660-8060
212-660-8098
Other Info
Consonance Capital Management LP, a Delaware Limited Partnership, boasts a team of 14 employees, 8 of which work in advisory roles. Although it is unknown how many clients they serve, the firm's registration status with the U.S. Securities and Exchange Commission is listed as Approved, which was last reported on March 30th, 2012.
Consonance Capital | Healthcare Investors | United States
Consonance Capital is a healthcare investment platform that invests broadly across the healthcare landscape. Consonance Capital Management is a long/short public equity manager and Consonance Capital Partners is a private equity manager.
Direct Owners
-
BENNY NMN SOFFER
FOUNDER & PARTNER owns more than 10% but less than 25%
-
CONSONANCE CAPMAN GP LLC
GENERAL PARTNER owns more than 50% but less than 75%
-
EDWARD JAMES COOK
CHIEF COMPLIANCE OFFICER owns less than 5%
-
KEVIN HAROLD LIVINGSTON
FOUNDER & PARTNER owns more than 10% but less than 25%
-
MITCHELL JONATHAN BLUTT
FOUNDER, PARTNER & CHIEF EXECUTIVE OFFICER owns less than 5%
-
MARIA DE LEON
CHIEF COMPLIANCE OFFICER owns less than 5%
Indirect Owners
-
MITCHELL JONATHAN BLUTT
MANAGER AND MEMBER owns 75% or more
Prime Brokers
-
GOLDMAN SACHS & CO. LLC
United States -
NATIONAL FINANCIAL SERVICES LLC
United States
Firms Located Nearby
- CIP Fund Management LLC
- Blue WOLF Capital Partners LLC
- Sagewind Capital LLC
- Central Park Advisers LLC
- King Street Capital Management LP
- Prager Metis Wealth Management
- Siridean Advisors LLC
- Goldentree Asset Management Credit Advisor LLC
- Investcorp Credit Management US LLC
- TOMS Capital Investment Management LP
Top Holdings
- B. Riley Wealth Management, Inc. $167,022k
- UNIQURE N.V. $149,386k
- Iovance Biotherapeutics Inc $143,512k
- PACIRA BIOSCIENCES $121,768k
- RETROPHIN INC COM $76,593k
- Catalyst Pharmaceuticals Inc $68,643k
- UNITED THERAPEUTICS CORP DEL $60,166k
- EPIZYME INC $59,739k
- VERICEL CORP $55,388k
- UROGEN PHARMA LTD $51,530k